Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX

Objective

ArAv87 is a broad-spectrum, human-like, anti-L1, recombinant antibody, developed by IRBA, that neutralizes in vitro the four orthopoxvirus infectious for humans. In the plaque reduction assay, the IC50 values of ArAv87 are 83.9ng·mL⁻¹ for vaccinia virus, below 18.5 ng·mL⁻¹ for cowpox virus, 20 ng·mL⁻¹ for monkeypox virus and 1 ng·mL⁻¹ for variola major virus. Currently, there is no specific therapy for orthopoxvirus infections, that can be produced and used in a large scale. Therefore, ArAv87 antibody is a promising broad-spectrum molecule for the prevention and the therapy of diseases induced by orthopoxvirus, in a natural (pandemic) or intentional (bioterrorist or biowarfare attack) context.
In THANATOS, ArAv87 will be optimized to increase its affinity, its clinical tolerance, its manufacturability and its stability. An original and efficient approach combining artificial intelligence and gold-standard conventional techniques of laboratory will be used to realize this optimization with a very limited time and funds. Optimized ArAv87 antibody will be tested in vivo against mpox in mice and non-human primate model. Then, the preclinical development of optimized ArAv87 will be realized, to guaranty the safety and efficacy of the antibody before the first-in-human study. After the production under GMP conditions, the clinical safety of this antibody will be evaluated in a clinical trial phase 1 in cohorts of healthy volunteers.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-HLTH-2025-01

See all projects funded under this call

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 3 234 834,25
Address
RUE LEBLANC 25
75015 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (9)

Partners (1)

My booklet 0 0